Linked Life Data

17344944

Source:http://linkedlifedata.com/resource/pubmed/id/17344944

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-3-8
pubmed:abstractText
Appetite suppression is one of the most common side effects of methylphenidate (MPH), which is used for treatment of attention-deficit hyperactivity disorder (ADHD). Relation of appetite and leptin is well known but there is no report regarding MPH use and leptin. In this study we compared the baseline leptin levels of ADHD children with the controls and studied the interaction between MPH and leptin-insulin level in ADHD children under MPH treatment. The major finding of this study is that at a total daily dose of 0.6 mg/kg short-acting MPH treatment, one does not observe significant side effects related to appetite suppression and metabolic features as measured via body mass index, insulin and leptin levels. Thus this range seems to be safe in developing ADHD children with minimum side effects regarding appetite for short-term treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0379-0355
pubmed:author
pubmed:copyrightInfo
(c) 2007 Prous Science. All rights reserved.
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
47-52
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:articleTitle
Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
pubmed:affiliation
Department of Child and Adolescent Psychiatry, Gazi University School of Medicine, Ankara, Turkey. ekaracan@gazi.edu.tr
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't